Cost-effectiveness study of influenza vaccination for people aged 50-64 years in Italy;Studio costo-efficacia della vaccinazione influenzale per gli italiani di età compresa tra 50 e 64 anni

PharmacoEconomics - Italian Research Articles

Volumn 9, Issue 2, 2007, Pages 91-101

  Gasparini, Roberto ^a   Lucioni, C ^b   Ansaldi, F ^a   Durando, P ^a   Sticchi, L ^a   Icardi, G ^a   Panatto, D ^a   Martin, M ^a   Chancellor, J ^c   Aballea S ^c  

^a UNIVERSITY OF GENOA   (Italy)

^b Wolters Kluwer Health/ADIS International   (Italy)

^c Innovus Research   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

INFLUENZA VACCINE;

ADULT; ANALYTIC METHOD; ARTICLE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; HOSPITALIZATION; HUMAN; IMMUNIZATION; INFLUENZA; INFLUENZA VACCINATION; ITALY; MAJOR CLINICAL STUDY; MEDICAL DECISION MAKING; QUALITY OF LIFE; REIMBURSEMENT; SOCIETY;

EID: 34748866694     PISSN: 15909158     EISSN: None     Source Type: Journal    
DOI: 10.1007/bf03320703     Document Type: Article

References (49)

1. Stephenson J, Zambon M. The epidemiology of influenza. Occup Med 2002; 5: 241-7
2. Nicholson KG. Impact of influenza and respiratory syncytial virus on mortality in England and Wales from January 1975 to December 1990. Epidemiol Infect 1996; 116: 51-63
3. Thomson WW, Shay DK, Weintraub E, et al. Mortality associated with influenza and respiratory syncytial virus in United States. JAMA 2003; 289: 179-86
4. Ministero della Salute. INFLUNET - www.influnet.it.
5. Congress of US Office of Technology Assessment. Cost Effectiveness of Influenza Vaccination. Washington, DC: US Printing Office, 1981: 1-67
6. Gasparini R, Pozzi T, Bonanni P, et al. Valutazione dei costi di un'epidemia influenzale nella popolazione lavorativa di Siena. Giornale di Farmacoeconomia 2000; 4: 3-9
7. Lucioni C, Costa B, Sessa A. I costi dell'influenza in Italia. Farmacoeconomia e Percorsi Terapeutici 2001; 2: 11-8
8. Jefferson T, Rivetti D, Rivetti A, et al. Efficacy and effectiveness of influenza vaccines in elderly people: a systematic review. Lancet 2005; 366: 1165-74
9. CIRI-IV, Centro Interuniversitario per lo studio dell'influenza e le altre infezioni virali: www.influciri.it.
10. Bridges CB, Harper SA, Fukuda K, et al. Prevention and control of influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2003; 52: 1-34
11. Francis PJ. Optimal tax/subsidy combinations for the flu season. J Econ Dyn Control 2004; 28: 2037-54
12. Nichol KL, Mendlman P. Influence of clinical case definitions with differing levels of sensitivity and specificity on estimates of the relative and absolute health benefits of influenza vaccination among healthy working adults and implications for economic analysis. Virus Res 2004; 103: 3-8
13. Classification Committee of WONCA, ICHPP-2-Defined. Inclusion criteria for use of the rubrics of the International Classification Problems in Primary Care. New York: Oxford University Press Inc, 1983
14. Busschbach JJ. A comparison of EQ-5D time trade off value obtained in Germany, the United Kingdom and Spain. In: Brooks R, Rabin R, de Charro FTH, editors. The measurement and valuation of health status using EQ-5D: a European perspective. Kluwer Academic Publishers 2003: 143-6
15. Osservatorio Nazionale sulla Salute nelle Regioni Italiane. Rapporta Osservasalute - Stato di salute e qualitè dell'assistenza nelle regioni italiane. Milano: Vita e Pensiero, 2004
16. Eurostat: http://www.eu.int/comm/eurostat
17. Istituto Superiore di Sanità. FLU-ISS. Sistema di sorveglianza sentinella dell'influenza basata su medici di medicina generale e pediatri di libera scelta. Roma Rapporti ISTISAN 2002, 02/19
18. Istituto Superiore di Sanità. FLU-ISS. Sistema di sorveglianza sentinella dell'influenza basata su medici di medicina generale e pediatri di libera scelta. Roma: Rapporti ISTISAN 2003, 03/36
19. Istituto Superiore di Sanità. FLU-ISS. Sistema di sorveglianza sentinella dell'influenza basata su medici di medicina generale e pediatri di libera scelta. Roma: Rapporti ISTISAN 2004, 04/24
20. Gasparini R, Lucioni C, Lai P, et al. Influenza surveillance in the Italian region of Liguria in the winter of 1999-2000 by general practitioners and paediatricians: socio-economics implications. J Prev Med Hyg 2001; 42: 83-6
21. Gasparini R, Ciliberti A, Gulino M, et al. Patient information, attitude and behaviour concerning influenza vaccination at the polyclinic of Siena. J Prev Med Hyg 2003; 44: 15-8
22. Gasparini R, Montomoli E, Sticchi L, et al. Health care workers: their knowledge and behaviour with respect to influenza vaccination. J Prev Med Hyg 2003; 44: 41-7
23. Gasparini R, Pozzi T, Giotti M, et al. Excess hospitalization for respiratory illnesses during influenza epidemics in Siena between 1987 and 1990. J Prev Med Hyg 1992; 33: 107-10
24. Demicheli V, Jefferson T, Rivetti D, Deeks J. Prevention and early treatment of influenza in healthy adults. Vaccine 2000; 18: 957-1030
25. Gross PA, Hermogenes AW, Sacks HS, et al. The efficacy of influenza vaccine in elderly persons. A meta-analysis and review of literature. Ann Intern Med 1995; 123: 518-27
26. Akoi FY, Fleming DM, Griffin AD, et al. Impact of zanamivir treatment on productivity, health status and healthcare resource use in patients with influenza. Zanamivir Study Group. Pharmacoeconomics 2000; 17: 187-95
27. Burls A, Clark W, Steward T, et al. Zanamivir for the treatment of influenza in adults: a systematic review and economic evaluation. Health Technol Assess 2002; 6: 1-87
28. Turner D, Wailoo A, Nicholson K, et al. Systematic review and economic decision modelling for the prevention and treatment of influenza A and B. Health Technol Assess 2003; 7: 1-182
29. GioFil: http://www.giofil.it/offline/SOuauett.htm
30. Dal Negro R, Rossi A, Cerveri I. The burden of COPD in Italy: results from confronting COPD survey. Resp Med 2003; 97 (Suppl. C): S43-50
31. Ministero della Salute: http://www.ministerosalute.it
32. Colombo GL, Nicosia V, Lesma A, et al. Analisi costi-benefici di una strategia vaccinale antinfluenzale condotta presso una società del gruppo ENI (Snamprogetti). Pharmacoeconomics-Italian Research Articles 2001; 3: 71-80
33. Lucioni C, Costa B, Sessa A. I costi dell'influenza in Italia. Farmacoeconomia e Percorsi Terapeutici 2001; 2: 11-8
34. Gasparini R, Pozzi T, Bonanni P, et al. Valutazione dei costi di un'epidemia influenzale nella popolazione lavorativa di Siena. Giornale di Farmacoeconomia 2000; 4: 3-9
35. Gasparini R, Lucioni C, Lai P, et al. Cost-benefit evaluation of influenza vaccination in the elderly in the Italian region of Liguria. Vaccine 2002; 20 (Suppl. 5): B50-4
36. WHO. WHO urges an increase in influenza vaccination. Sito internet: www.who.int/mediacentre/news/relas.es/pr70/en/ Ultima consultazione 17.03.2006
37. CDC. Influenza vaccination coverage levels. Sito internet: www.cdc.goc(flu/professionals/vaccination/coveragelevels.htm
38. Chucholowius HW, Rott R. A new method for purification of myxoviruses by zonal centrifugation with two different sucrose density gradients. Proc Soc Exp Biol Med 1972; 140: 245-7
39. Kunz C, Hoffmann H, Bachmayer H, et al. A new influenza vaccine: reactogenicity and antigenicity in comparison to split and whole virus vaccines. Infection 1976; 4: 73-9
40. Public Health Service Advisory Committee on Immunization Practices. Influenza vaccine: preliminary statement. Recommendations of the Public Health Service Advisory Committee on Immunization Practices. Ann Intern Med 1978; 89: 373-4
41. Wood JM, Seagroatt V, Schild GC, et al. International collaborative study of single-radial-difrusion and Immunoelectrophoresis techniques for the assay of haemagglutinin antigen of influenza virus. J Biol Stand 1981; 9: 317-30
42. CDC. Monovalent Influenza (HIN1) vaccine 1986-87. MMWR 1986; 35: 517-21
43. Commissione delle Comunità Europee, Commissione per le Biotecnologie e i Prodotti Farmaceutici. Relazione finale del meeting sui vaccini influenzali. Bruxelles, 1 marzo 1992. Decreto Ministro Sanità del 27 aprile 1992: Disposizioni sulle documentazioni tecniche da presentare a corredo delle domande di autorizzazione all'immissione in commercio di specialità medicinali per uso umano, anche in attuazione della Direttiva n. 91/507/CEE. Supplemente Ordinario Gazzetta Ufficiale n. 139 del 15 giugno 1992
44. Ansaldi F, Icardi G, Gasparini R, et al. New A/H3N2 influenza variant: a small genetic evolution but a heavy burden on the Italian population during the 2004-2005 season. J Clin Microbiol 2005; 43: 3027-9
45. Nichol KL. Cost-benefit analysis of a strategy to vaccinate healthy working adults against influenza. Arch Intern Med 2001; 161: 749-59
46. Lee PY, Matchar DB, Clements DA, et al. Economic analysis of influenza vaccination and antiviral treatment for healthy working adults. Ann Intern Med 2002; 137: 225-31
47. Hak E, Buskens E, van Essen GA. Clinical effectiveness of influenza vaccination in persons younger than 65 years with high-risk medical conditions: the PRISMA study. Arch Intern Med 2005; 165: 274-80
48. Turner D, Wailoo A, Nicholson KL, et al. Systematic review and economic decision modelling for the prevention and treatment of influenza A and B. Health Technol Assess 2003; 7: 1-182
49. Aballéa S, Chancellor J, Martin M, et al. The cost-effectiveness of influenza vaccination for people aged 50 to 64 years: an international model. Value Health 2007; 10: 98-116